Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM.
Primary glioblastoma multiforme (GBM) commonly overexpresses the epidermal growth factor receptor (EGFR) gene and its ligand-independent mutant, EGFRvIII. Amplification of the EGFR gene has been implicated in the pathogenesis of primary GBM, in particular the small cell phenotype, and this finding may contribute to its aggressive clinical behavior. Anti-EGFR clinical trials for GBM are being conducted, and it would be useful to identify a rapid technique to determine whether EGFR expression and the small cell phenotype are associated with a response to therapy. In the present study we examined 56 cases of GBM using chromogenic in situ hybridization (CISH). CISH analysis and morphology identified 22 small cell (SCGBM) and 22 non-small cell glioblastoma (NSCGBM), and 12 cases of a mixed phenotype. Fourteen cases of SCGBM (14/22) showed EGFR amplification, while only 5 NSCGBM (5/22) cases showed amplification. We have therefore used CISH as an efficient, economic and reliable means for routinely assessing EGFR amplification in GBM, including the small cell variant.
Quezado
M
M
Laboratory of Pathology, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA.
Ronchetti
R
R
Rapkiewicz
A
A
Santi
M
M
Blumenthal
D T
DT
Rushing
E J
EJ
D001932:Brain Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology*; D018288:Carcinoma, Small Cell / Q000235:genetics / Q000473:pathology; D048429:Cell Size; D002863:Chromogenic Compounds / Q000032:analysis; D066246:ErbB Receptors / Q000235:genetics*; D005784:Gene Amplification / Q000235:genetics; D005909:Glioblastoma / Q000145:classification / Q000235:genetics* / Q000473:pathology*; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods
D002863:Chromogenic Compounds; D066246:ErbB Receptors